New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
09:51 EDTDVA, FMSRevised CMS ruling favorable for dialysis providers, says Wells Fargo
Wells Fargo said the Centers for Medicare & Medicaid Services eliminated the impact of the rebase in its revised rules from for its proposed accountable care demonstration project for dialysis providers, which is a positive for the providers. The firm keeps an Outperform rating on DaVita HealthCare (DVA) and a Market Perform rating on Fresenius Medical (FMS).
News For DVA;FMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
10:01 EDTFMSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:09 EDTFMSFresenius Medical downgraded to Equal Weight from Overweight at Barclays
06:40 EDTFMSFresenius Medical downgraded to Neutral from Buy at UBS
UBS downgraded Fresenius Medical to Neutral citing limited upside to shares.
January 16, 2015
10:47 EDTDVABofA/Merrill healthcare facilities analyst analyst/industry conference call
Healthcare Facilities & Managed Care Analyst Bressler discusses the legislative and regulatory outlook for the industry for 2015 on an Analyst/Industry conference call to be held on January 23 at 2 pm.
January 15, 2015
09:17 EDTFMSFlamel Technologies weakness creates buying opportunity, says SunTrust
Subscribe for More Information
08:47 EDTFMSFlamel Technologies price target lowered to $17 from $22 at Roth Capital
Roth Capital cut its price target on Flamel (FLML) after the FDA approved Fresenius Kabi's (FMS) New Drug Application for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. Roth expects eostigmine to become a two player market, but adds that price increases by Flamel could mitigate the negative impacts on Flamel's growth. The firm keeps a Buy rating on Flamel.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use